33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: Results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX-973
33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: Results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX-973
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started